A Medical Breakthrough Attained by GWHP as a Leading Researcher, Believes a Dementia Diagnostics Test Will Save Lives
20 Abril 2021 - 6:18AM
InvestorsHub NewsWire
Global, a multinational supplier of
over 70+ FDA Approved Diagnostic Tests, attains breakthrough on
rising neurological disease testing.
San Clemente, CA -- April 20, 2021 -- InvestorsHub NewsWire --
Global WholeHealth Partners (OTC:GWHP)
now has the means to identify and test for Dementia using a
Micro-Well Reader or Lateral Flow Test to measure the certain brain
enzymes during the data collection process used in a positive
diagnosis. This was disclosed in an 8K filed March 21, 2021
which can be found by clicking here. "This could simply be described as
nothing short of a Medical Breakthrough in Dementia Diagnostic
Testing.” -- said Charles Strongo, CEO of Global WholeHealth
Partners, Corp (OTC:GWHP).
“We believe this announcement couldn’t come at a better time for
us as we are partnering with Nunzia Pharmaceutical and their
products for Neurological disorders,” said Mr. Strongo. “Nunzia
Pharmaceutical with nutraceutical for anxiety and stress based on
their patented formula and their pharmaceutical drug they are
planning on bringing through the FDA, which specifically works on
the Hippocampus part of the brain, dealing with stress, memory, and
fine motor skills are a perfect fit for Global’s diagnostic tests,”
says Mr. Strongo. Nutritional deficiencies: Not drinking
enough liquids (dehydration); not getting enough thiamin (vitamin
B-1), which is common in people with chronic alcoholism; and not
getting enough vitamins B-6 and B-12 in your diet can cause
dementia-like symptoms. Copper and vitamin E deficiencies also can
cause dementia symptoms: https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013.
“Early detection for Dementia disease is not only crucial for
patients and their quality of life, but this data is also used by
researchers to seek out commonalities, causes and hopefully cures,”
commented Strongo.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth
Partners Corp, said, "The Company's goal is to offer the fastest
and most reliable in-vitro diagnostic tests on the market, while
keeping ahead in R&D, by offering FDA Approved Troponin I Whole
Blood, Influenza A & B, and Strep A. The Company also has
international testing, which is not sold in the USA, with an FDA
Certificate of Exportability (2260-11-2019) for tests like ZIKA,
Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid
Tuberculosis (TB), Rapid Malaria, and many other rapid
tests."
GWHP develops, manufactures, and markets in vitro diagnostic
(IVD) tests for OTC, or consumer-use as well as professional rapid
diagnostic point-of-care (POC) test kits for hospitals, physicians’
offices, and medical clinics in the US and abroad. The Company has
the capacity to deliver hundreds of thousands of tests, and can
ramp up to 1 million tests per day. Currently, the Company has 56
products FDA approved and many are Approved for OTC use, and 9
POC products approved by the FDA.
Media Contact:
Name: Charles Strongo, CEO, Global WholeHealth Partners
Corp.
Email: Sales@gwhpcorp.com
Phone for Sales: 949-324-6691
www.gwhpcorp.com
This press release contains "forward-looking statements.” Such
statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market acceptance of our existing
and new products, (ii) negative clinical trial results or lengthy
product delays in key markets, (iii) an inability to secure
regulatory approvals for the sale of our products, (iv) intense
competition in the medical device industry from much larger,
multinational companies, (v) product liability claims, (vi) product
malfunctions, (vii) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (viii) insufficient or
inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or
regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for
certain product components, (xii) the fact that we will need to
raise additional capital to meet our business requirements in the
future and that such capital raising may be costly, dilutive or
difficult to obtain and (xiii) the fact that we conduct business in
multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications
challenges, burdens and costs of compliance with foreign laws and
political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set
forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC's web site at http://www.sec.gov. The Company assumes no obligation
to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024